Safety Study of AMG 228 to Treat Solid Tumors

• Status: Terminated
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen

Criteria

Inclusion Criteria:

• Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor

• Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Exclusion Criteria:

• Active autoimmune disease, history of autoimmune disease

• Treatment with immune modulators including

• Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors

• Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days

• Major surgery within 28 days of study day 1